Cue Biopharma reports positive Phase 2 topline results for CUE-221
Cue Biopharma said CUE-221 met dose-responsive primary and secondary endpoints in chronic spontaneous urticaria, with a favorable safety profile and durable benefit versus placebo and omalizumab.